[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.12% 84.10 83.60 84.60 84.40 83.60 84.40 243,149 16:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 34.3 383

Ekf Diagnostics Share Discussion Threads

Showing 3651 to 3675 of 3875 messages
Chat Pages: 155  154  153  152  151  150  149  148  147  146  145  144  Older
DateSubjectAuthorDiscuss
18/6/2021
17:50
I don't either, but tong does!
jacks13
18/6/2021
17:41
@jacks13 whoosh over my head. I get the jist but not sure how I could apply that to investing
senseibull
18/6/2021
16:47
Do you trade very often? Https://www.zmescience.com/science/what-5-sigma-means-0423423/
jacks13
18/6/2021
16:24
I don't pay attention to the usual resistance lines etc (or TA in general for that matter). It will all depend on the health of the tape instead. Example: I may not get in if we close next Monday at 86 but happier to get in at 95 a few days later instead if the tape is healthier on the latter. For me this is not about buying cheap at all costs but rather buying at the right time (when odds are overwhelming for a strong follow through). Usually I arrive at my decision (I observe my watchlist daily even though I may not get in for weeks or months unless the stars align) by putting both price and volume in a joint historical context where deviations normally exceed 5 sigmas in magnitude.
tongosti
18/6/2021
15:36
@tongosti What’s your buy in past resistance price?
senseibull
18/6/2021
10:23
Constructive price action. Looks like it wants to break through the ceiling but not there yet. Tic toc
tongosti
18/6/2021
07:50
Given where the vast majority of Novo Holdings (wholly owned by the Novo Nordisk Foundation) investments are targeted, the following acquisition is another strong indication that the perception and understanding of diagnostics has changed and that diagnostics has entered a major growth phase - Novo acquires BBI in £400m+ deal 17 JUNE 2021 09:27 Life sciences investor Novo Holdings has acquired BBI Group, a supplier of products and services to the global diagnostics and life sciences industries, from Exponent for an enterprise value of over £400 million. Full story - hTTps://www.med-technews.com/news/medtech-merger-acquisition-finance-and-investment-news/novo-acquires-bbi-in-400m-deal/
wan
17/6/2021
08:29
Thank you wan
shanklin
17/6/2021
08:26
Shanklin...EKF produce/supply PrimeStore MTM and also produce/supply PBS - The collection mediums perhaps have different uses/applications. And I note that the test is also authorised for the qualitative detection of nucleic acid from SARS-CoV-2 in pooled samples containing up to five individual anterior nasal swab specimens per pool that are collected in individual vials containing transport medium. So this may be one such derivative. We can only make an educated guess (that it's Amazon) based on our knowledge that EKF signed of a multi-million dollar global supply contract with a very large private sector partner. And that additional production lines for Phosphate Buffered Saline (PBS) was established Q1 2021 at the following EKF sites - Boerne, South Bend, Barleben and Cardiff.
wan
17/6/2021
08:12
So Amazon are dual sourcing?
shanklin
17/6/2021
08:07
For interest/clarification, Amazons FDA cleared test kit utilises 'either' PrimeStore MTM, or a Phosphate Buffered Saline (PBS). Kit assembly/source yet to be confirmed!
wan
17/6/2021
07:55
Potentially disruptive? Amazon is selling its own FDA-approved COVID-19 test kit directly to consumers for $39.99 each as retail giant continues march into healthcare industry By MANSUR SHAHEEN FOR DAILYMAIL.COM PUBLISHED: 18:59, 16 June 2021 | UPDATED: 19:01, 16 June 2021 Amazon is selling its own at-home COVID-19 test kit directly to consumers. The kit, which received approval from the U.S. Food and Drug Administration (FDA) in March 2021, will cost $39.99. Kits come with a swab kit and a prepaid shipping label to be returned to an Amazon lab for analysis with some kits available via one-day shipping through Prime, reported STAT News. Results of the tests will later be available of AmazonDX.com, the companies diagnostics page. While the pandemic nears its end, at home testing kits for COVID-19 and other viruses that can be tested for via a simple nose swab are only becoming more commonplace. There are already other non-Amazon branded at-home COVID-19 test kits available on the online retailer, all costing around $90 to $100, more than double the price of Amazon's test. There are also other forms of at-home testing that have risen to prominence during the pandemic, like at home colon caner screening. Some experts are also hopeful that gains made over the past month in developing at-home tests will make at-home testing common place for even more viruses, like the common flu. It comes as Amazon undergoes an expansion into the health care world. Full story - hTTps://www.dailymail.co.uk/health/article-9693499/Amazon-sell-home-COVID-19-test-kit-40-retail-giant-continues-march-healthcare.html
wan
16/6/2021
16:15
US Update - UPDATE: June 16, 2021: Amazon's COVID-19 test, which got FDA emergency authorization in March, was originally designed for use by company employees but is now available for $39.99 to the public. Consumers use a nasal self-swab at home that is sent to a centralized lab for processing, with a website provided for viewing their results. hTTps://www.medtechdive.com/news/amazon-gets-eua-for-direct-to-consumer-at-home-covid-19-test/601511/
wan
16/6/2021
08:00
Obviously we already know EKF is well resourced in terms of cash and investments and cashflow, and although funding of the growth strategy has been on my mind, with today's announcement I am wondering what form, if any, it might take. Thus, an update on this aspect would be helpful, but I am sure this will feature at some point. In any regard, I completely trust EKF's management, along with being very optimistic indeed about the growth strategy.
wan
14/6/2021
07:20
From SourceBio's AGM Statement this morning - The Executive Chairman's AGM statement is produced below: SourceBio has continued to trade well since 31 December 2020 with revenues, earnings and cash generation in the year-to-date significantly ahead of the equivalent period last year. In relation to COVID-19 testing opportunities, the Group has moved quickly to evolve with the fast-paced and ever-changing market requirements necessary to support the ongoing testing needs in battling this pandemic. The Group remains focussed on expanding its offerings, technologies and routes to market and has also pivoted away from the heavy reliance on PCR testing for the Department of Health and Social Care (DHSC) that initially underpinned the Infectious Disease Testing business unit. SourceBio now supports a much broader portfolio of customers with whom we are already working or who are part of our growing pipeline. The Board is pleased with progress in the year-to-date but recognises that it expects peak levels of revenue and earnings to be generated from the anticipated high levels of travel related testing expected in the coming months. The indicated demand of such travel related testing has provided the impetus to further expand the capacity of our Nottingham laboratory. We are also pursuing additional laboratory capacity elsewhere in the UK in order to cope with the anticipated peak in demand. If the forecasted volumes of business materialise, we would expect the 2021 financial results to be materially second-half weighted. The Group's base business lines have now all returned to pre-pandemic levels of trading. In the Healthcare Diagnostics business unit, we are pleased to report that we have seen progressive increases in the volume of Cellular Pathology business returning to us in recent months as the numbers of elective surgeries now appear to be increasing with some momentum. This business was the final offering within our three well-established business units (Healthcare Diagnostics, Genomics and Stability Storage) to return to more regular pre-COVID-19 levels of trading. We continue our pursuit of strategically relevant, earnings enhancing acquisitions to augment the growth of our established business units and to further strengthen our capabilities and offerings to customers. The key criteria when exploring potential acquisitions will be how we can integrate these businesses into our current model to achieve accretive earnings. The Group remains well positioned to support its customers and their requirements and we remain optimistic for the remainder of the year and beyond. hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-AGM-Statement/85346795
wan
11/6/2021
14:53
You haven't missed a beat chap. Share price doing still same old.
tongosti
11/6/2021
12:00
I have been somewhat tied-up with other matters of late. The following is interesting, and the reference to point of care, appears on the face of it, to align with some of my previous thoughts - Longhorn Vaccines & Diagnostics to Present at 2021 BIO Digital June 10, 2021 BETHESDA, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, announced today that it has been selected to deliver a presentation on the past success and future opportunities for its lead product, PrimeStore MTM (Molecule Transport Medium) as well as introduce the rest of the company’s product line, at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 and 14-18, 2021, and presentations will be available on-demand throughout the event. Jeff Fischer, President and Co-Founder, will present the company and PrimeStore MTM, which was the first microbial nucleic acid storage and transport device cleared by the U.S. Food and Drug Administration. PrimeStore MTM quickly inactivates viruses (including COVID-19, influenza), bacteria (including tuberculosis), and pathogens within the sample while preserving RNA and DNA for testing. The presentation will be available to registered attendees beginning at 9 a.m. ET on June 10. “While PrimeStore MTM and the Longhorn product line is well known within the Molecular Diagnostic community, we’re looking forward to presenting PrimeStore MTM to a wider pharmaceutical and biotech audience at BIO so that attendees can see the impact that our state-of-the-art diagnostic tools have on improving the safety, sensitivity, and cost efficiency of clinical trials, point of care, and hospital testing,” said Jeff Fischer, President at Longhorn. “In the past year-and-a-half we’ve been able to demonstrate our company’s ability to deliver high volume and custom solutions directly and through our current partnerships.” hTTps://www.businesswire.com/news/home/20210610005253/en/Longhorn-Vaccines-Diagnostics-to-Present-at-2021-BIO-Digital
wan
11/6/2021
08:01
https://www.ekfdiagnostics.com/logistics-a-total-meltdown.html Download article and read on: "A step in the right direction However, it’s not just vaccines, but also lab work that’s moving away from the cold chain. EKF Diagnostics’ PrimeStore MTM device stabilises and preserves sample RNA for up to seven days at ambient temperatures, allowing it to be transported and processed outside of containment. The device has come into its own during the pandemic, taking pressure off labs that do not have the capacity to refrigerate large volumes of Covid-19 test samples onsite. It also reduces time and cost constraints for transportation because samples can be sent via the postal system rather than requiring specialist couriers........"
mirandaj
09/6/2021
16:49
Only a breakout north of 80 on huge volumes is the answer to your question. That's the only way one can be (reasonably) sure the market is playing ball.
tongosti
09/6/2021
13:08
I have every confidence that the trading statement will confirm the confidence and excitement regarding prospects that I read in from the directors. A question I have though if the announcement can contain at this stage the categoric confirmations that the market seems to crave. Time will tell.
ppmm
09/6/2021
11:29
charlie - ok well I clearly reported that wrong from the AGM. NEver mind
faz
09/6/2021
07:31
Maybe - let's see what today will bring.
tongosti
08/6/2021
20:16
Ignore it - UTs are highly unpredictable. It will highly likely open within a tad of the closing bid offer
davr0s
08/6/2021
19:55
Wow closing at the day's low. As they say patience is a virtue.
tongosti
08/6/2021
17:59
FazPost 1920You said.."Trading update wc 7 June and a roadshow same week."That was on the day of the AGM if I'm not mistaken. Strange
charlieej
Chat Pages: 155  154  153  152  151  150  149  148  147  146  145  144  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 03:25:43